Research focuses on thoracic cancer biology and translational biomarkers. Integrates immunohistochemistry and molecular profiling to refine prognosis and guide therapy in non–small-cell lung cancer and mesothelioma, evaluating DNA repair pathways, tumor mutational metrics, and outcomes in cooperative‑group clinical trials.